

Arden and Greater East Midlands Commissioning Support Unit in association with Lincolnshire Clinical Commissioning Groups, Lincolnshire Community Health Services, United Lincolnshire Hospitals Trust and Lincolnshire Partnership Foundation Trust

Lincolnshire *PACE* Shorts

Summary of PACEF decisions from January/February 2016

For further details see *PACE Bulletin* Volume 10; Number 4 (February 2016)

Drug	Indication(s)	Traffic Light and <i>Joint Formulary</i> Status
Apremilast 10mg, 20mg and 30mg tablets (Otezla) (Celgene)	For the treatment of moderate to severe chronic plaque psoriasis in adults who have failed to respond to, have a contraindication to, or are intolerant to other systemic therapy including ciclosporin, methotrexate or PUVA.	RED-RED Not approved for inclusion in the Lincolnshire Joint Formulary for this indication.
Apremilast 10mg, 20mg and 30mg tablets (Otezla) (Celgene)	For the treatment of active psoriatic arthritis in patients with an inadequate response or intolerance to DMARDs.	RED-RED Not approved for inclusion in the Lincolnshire Joint Formulary for this indication.
Bortezomib 3.5mg injection (Velcade) (Janssen-Cilag Ltd)	For use, in combination with rituximab, cyclophosphamide, doxorubicin and prednisone in the treatment of adult patients with previously untreated mantle cell lymphoma who are unsuitable for haematopoietic stem cell transplantation.	RED. Approved for inclusion in the Lincolnshire Joint Formulary for this indication. Also approved for use: • as monotherapy for relapsed progressive multiple myeloma (NICE TA129) • in combination with thalidomide for the first line treatment of multiple myeloma (NICE TA228). • in combination with other agents for the induction therapy of previously untreated multiple myeloma (NICE TA311).
Ciclosporin 0.1% single use eye drops (Ikervis) (Santen UK Ltd)	For the treatment of severe keratitis in dry eye disease unresponsive to tear substitutes.	RED Approved for inclusion in the Lincolnshire Joint Formulary. Local treatment guidelines are in development.
Erlotinib 25mg, 100mg and 150mg tablets (Tarceva) (Roche Products Ltd)	For the treatment of locally advanced or metastatic non-small cell lung cancer after failure of previous chemotherapy.	RED Approved for inclusion in the Lincolnshire Joint Formulary for this indication. NB Erlotinib is not recommended for treating locally advanced or metastatic non-small-cell lung cancer that has progressed after non-targeted chemotherapy in people with tumours that are EGFR TK mutation-negative.
Ethinylloestradiol 0.02mg/ drospirenone 3 mg tablets (Daylette) (Consilient Health Ltd)	Contraception	GREEN Approved for inclusion in the Lincolnshire Joint Formulary.

Ethinylloestradiol 0.02mg/ drospirenone 3 mg tablets (Eloine) (Bayer)	Contraception	RED-RED Not approved for inclusion in the Lincolnshire Joint Formulary.
Fentanyl sublingual tablets 100mcg, 200mcg, 300mcg, 400mcg, 600mcg, 800mcg (Abstral) (ProStrakan)	Breakthrough pain in opioid therapy for chronic cancer pain.	GREEN Approved for inclusion in the Lincolnshire Joint Formulary. Third line after (1) immediate release morphine and (2) immediate release oxycodone.
Fentanyl lozenges 200mcg,400mcg, 600mcg, 800mcg, 1200mcg and 1600mcg (Actiq) (Teva UK)	Breakthrough pain in opioid therapy for chronic cancer pain	RED-RED Not approved for inclusion in the Lincolnshire Joint Formulary.
Fentanyl buccal film sachet 200mcg, 400mcg and 800mcg (Breakyl) (Meda)	Breakthrough pain in opioid therapy for chronic cancer pain	RED-RED Not approved for inclusion in the Lincolnshire Joint Formulary.
Fentanyl buccal tablets 100mcg, 200mcg, 400mcg, 600mcg and 800mcg (Effentora) (Teva UK)	Breakthrough pain in opioid therapy for chronic cancer pain	GREEN Approved for inclusion in the Lincolnshire Joint Formulary. Third line after (1) immediate release morphine and (2) immediate release oxycodone.
Fentanyl nasal spray 50mcg/dose, 100mcg/dose, 200mcg/dose (Instanyl) (Takeda)	Breakthrough pain in opioid therapy for chronic cancer pain	RED-RED Not approved for inclusion in the Lincolnshire Joint Formulary.
Fentanyl nasal spray 100mcg/dose, 400mcg/dose (PecFent) (Archimedes)	Breakthrough pain in opioid therapy for chronic cancer pain	GREEN Approved for inclusion in the Lincolnshire Joint Formulary. Third line after (1) immediate release morphine and (2) immediate release oxycodone.
Fentanyl sublingual tablets 133mcg, 267mcg, 400mcg, 533mcg and 800mcg (Recivit) (Grunenthal)	Breakthrough pain in opioid therapy for chronic cancer pain	RED-RED Not approved for inclusion in the Lincolnshire Joint Formulary.
Gefitinib 250mg tablets (Iressa) (AstraZeneca UK Ltd)	For the treatment of locally advanced or metastatic non-small cell lung cancer with activating mutations of epidermal growth factor receptor	Gefitinib is already included on the Lincolnshire Joint Formulary as a RED drug for the treatment of lung cancer as recommended under NICE TA 192. Gefitinib is not recommended for treating locally advanced or metastatic non-small-cell lung cancer that has progressed after non-targeted chemotherapy in people with tumours that are EGFR mutation-positive. It is designated RED-RED for this indication.
Trastuzumab emtansine 100mg and 160mg for solution for infusion (Kadcyla) (Roche Products Ltd)	Monotherapy for the treatment of HER2-positive, unresectable, locally advanced or metastatic breast cancer, in adult patients who have previously received trastuzumab and a taxane separately or in combination.	RED-RED Not included in the Lincolnshire Joint Formulary.

RED-RED: This signifies that a product is **not recommended** for prescribing in **either** primary or secondary care. All new products are classified as RED-RED pending assessment by PACEF.

RED: This signifies that a product has been approved for use within secondary care, tertiary care or a primary care hosted specialist service only and **should not be routinely prescribed in primary care**. RED drugs may be used within ULHT or LPFT subject to approval for use within each Trust. ULHT and LPFT reserve the right to determine whether or not RED drugs will be used within their Trusts. RED classification does not automatically signify that a drug will be available within secondary/tertiary care.

AMBER: This signifies that a drug has been approved for use in primary care **subject to specialist initiation; a shared care guideline (SCG) may also be required**. The main purpose of the SCG will be to clearly define both specialist and GP responsibilities. Not all AMBER drugs that require SCGs are currently covered by formal documents; PACEF are working to rectify this.

GREEN: This signifies a product that is **approved for initiation in either primary or secondary care**.

This bulletin has been created specifically to convey details of decisions taken at the Prescribing and Clinical Effectiveness Forum (PACEF) to all stakeholders across the Lincolnshire Healthcare Community in both primary and secondary care. Back issues of the *PACE Bulletin* and *PACE Shorts* are available through the PACEF website (<http://lincolnshire-pacef.nhs.uk>); follow the commissioning link to PACEF. Electronic copies of the *PACE Bulletin* are circulated to a wide readership via email. If you are not currently on our distribution list and wish to receive regular copies of PACEF publications please contact Sandra France on sandra.france@gemcsu.nhs.uk.

Google searching can be a quick and effective way of finding back numbers of the *PACE Bulletin* relevant to a specific topic of interest. Searchers are advised to use the official version of the *Bulletin* available from the PACEF website rather than depend on a potentially unreliable draft or variant found through Google or an alternative search engine.

The *Lincolnshire Joint Formulary* is available on line and is fully searchable; it can be accessed at www.lincolnshirejointformulary.nhs.uk

THIS DOCUMENT IS INTENDED FOR USE BY NHS HEALTHCARE PROFESSIONALS ONLY AND CANNOT BE USED FOR COMMERCIAL OR MARKETING PURPOSES WITHOUT PERMISSION